NEW YORK, Sept. 17, 2015 /PRNewswire/ -- PR Newswire – XenoPort, Inc. (NASDAQ: XNPT) shares closed at $4.45 in yesterday's session, down nearly 34% from Monday. XenoPort announced a setback in its psoriasis drug X232829 as detailed in the Reuters report you will find below. The drug caused higher than expected side effects, specifically gastrointestinal, during its trial phase.
Our due diligence report will inform investors as to XNPT current events and what the future may hold. Get our brief report at the link below at no cost.
http://bit.ly/_XNPT_Due_Diligence
Copy and paste to browser may be required.
About XenoPort , Inc.
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and potentially for relapsing forms of multiple sclerosis. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This release and report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this release have not been compensated in any form by any source. A full disclaimer can be found by viewing due diligence. We are only human and may make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/attention-investors-xenoport-down-34-this-week---brokerbank-securities-provides-insights-300144685.html
SOURCE BrokerBank Securities, Inc.
